Form 4 Filing for Agios Pharmaceuticals, Inc.

This filing details transactions made by Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, Inc. On April 2, 2026, Gheuens acquired 8,500 performance share units (PSUs) with a reported value of $0.00 per share. These PSUs represent a contingent right to receive common stock. Simultaneously, 8,500 PSUs were disposed of, with the underlying security being common stock. Gheuens also disposed of 2,940 shares of common stock at a price of $34.71 per share to cover tax withholding obligations related to the vesting of her PSUs. This sale was executed under a Rule 10b5-1(c) trading plan. Additionally, 311 shares were purchased through the Company's employee stock purchase plan. Following these transactions, Gheuens holds 83,217 shares acquired through the employee stock purchase plan and 80,277 shares directly owned.